| Q42722415 | An overview of occult hepatitis B virus infection. |
| Q43034619 | Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load |
| Q38990467 | Anti-HBc screening in Egyptian blood donors reduces the risk of hepatitis B virus transmission |
| Q36980710 | Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus |
| Q36532419 | Epidemiology of Hepatitis B virus and genotype |
| Q46403776 | Evaluation of the antimicrobial activity and materials compatibility of orthophthalaldehyde as a high-level disinfectant |
| Q35131635 | Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening |
| Q36532429 | Genetic variation in HBV infection: genotypes and mutants |
| Q78859747 | Health and economic impact of posttransfusion hepatitis B and cost-effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union |
| Q36532451 | Hepatitis B virus (HBV) screening strategy to ensure the safety of blood for transfusion through a combination of immunological testing and nucleic acid amplification testing - Japanese experience |
| Q37153782 | Hepatitis B virus infection and transfusion medicine: science and the occult |
| Q40847895 | Infection Patterns Induced in Naive Adult Woodchucks by Virions of Woodchuck Hepatitis Virus Collected during either the Acute or Chronic Phase of Infection. |
| Q42277057 | Infectivity of blood products from donors with occult hepatitis B virus infection |
| Q90788873 | Interpretation of pathogen load in relationship to infectivity and pathogen reduction efficacy |
| Q40488494 | Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy |
| Q36466447 | New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods |
| Q42995031 | Occult hepatitis B in renal transplant patients |
| Q36812851 | Occult hepatitis B virus infection among Egyptian blood donors |
| Q35683881 | Reducing the risk of hepatitis B virus transfusion-transmitted infection |
| Q45409042 | Sensitivity of hepatitis B virus DNA transcription-mediated amplification testing in hepatitis B surface antigen-positive blood donations |
| Q35674392 | Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? |
| Q36306899 | Significance of Response to Hepatitis B Recombinant Vaccine in Subjects with Isolated Antibody to Hepatitis B Core Antigen |
| Q39238511 | Significance of anti-HBc alone serological status in clinical practice |
| Q41606333 | The yield of universal antibody to hepatitis B core antigen donor screening in the Netherlands, a hepatitis B virus low-endemic country |
| Q57205463 | Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers |